ANXA5 and hepatocellular carcinoma: Momelotinib, together with sorafenib, increased the sensitivity of HCC cells, resulting in decreased colony formation in cells treated with the combination, and also alleviated apoptotic markers (Annexin-V+ and 7-AAD positive cells) PARP-1, PDCD4, and Bax molecules (Figure 5).